The generic name for Basaglar is insulin glargine [1].
What is insulin glargine used for?
Insulin glargine is a long-acting insulin used to treat high blood sugar levels in adults and children with diabetes mellitus [1]. It helps control blood sugar when other diabetes medications are not enough [1].
How does insulin glargine work?
Insulin glargine is a modified form of human insulin that works by lowering blood glucose [1]. It is absorbed slowly and provides a relatively constant level of insulin over a 24-hour period [1].
When does Basaglar's patent expire?
The patent landscape for insulin glargine products like Basaglar is complex, involving multiple patents covering aspects such as the molecule itself, formulations, and methods of use [2]. While specific patent expiry dates can vary and are subject to legal challenges, information on drug patents and their expiration can be found on sites like DrugPatentWatch.com [2]. For example, key patents related to insulin glargine have had expiration dates in the mid-2020s, but the actual market entry of generics can be influenced by patent litigation and exclusivity periods [2].
Can biosimilars be approved before patent expiry?
In some cases, biosimilar versions of biologic drugs, including insulin glargine, can be approved and enter the market before all relevant patents expire, particularly if patent litigation is resolved in favor of the biosimilar applicant or if certain patents are deemed invalid or not infringed [3]. The approval pathway for biosimilars is distinct from small-molecule generics.
Who manufactures Basaglar?
Basaglar is manufactured by Eli Lilly and Company [1].
What are the risks associated with insulin glargine?
The primary risk associated with insulin glargine, like all insulins, is hypoglycemia, or low blood sugar [1]. Other potential side effects include allergic reactions, weight gain, and injection site reactions [1]. Patients with diabetic ketoacidosis should not use insulin glargine [1].